The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status

Cell Death and Differentiation

Volumn 9, Issue 7, 2002, Pages 702-709

  Crespo, N C ^a,b   Delarue, F ^a,b   Ohkanda, J ^c   Carrico, D ^c   Hamilton, A D ^c   Sebti, S M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

Bipolar spindles; FTase; FTIs; Mitosis; p53; Ras

Indexed keywords

FARNESYL TRANS TRANSFERASE; PROTEIN P53; RAS PROTEIN; TRANSFERASE; 4',6 DIAMIDINO 2 PHENYLINDOLE; DNA; FTI 2153; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; CELL STRAIN 3T3; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFORMATION; GENETICS; HUMAN; METABOLISM; METAPHASE; MITOSIS; MITOSIS SPINDLE; MOUSE; MUTAGENESIS; PHYSIOLOGY; ANIMAL CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMOSOME; CONTROLLED STUDY; CORRELATION ANALYSIS; FIBROBLAST; FIBROSARCOMA; GENE MUTATION; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG CANCER; MICROTUBULE; MITOSIS INHIBITION; MORPHOLOGY; NONHUMAN; OVARY CANCER; PREPUCE; PRIORITY JOURNAL; PROPHASE; STAINING;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL DIVISION; FARNESYLTRANSTRANSFERASE; HUMANS; METAPHASE; MICE; MITOSIS; MITOTIC SPINDLE APPARATUS; MUTAGENESIS; RAS PROTEINS; TRANSFORMATION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; ANIMAL; HUMAN; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035988368     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401023     Document Type: Article

References (30)

1. Protein prenylation: Molecular mechanisms and functional consequences
2. Farnesyltransferase and geranylgeranyl-transferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies
3. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
4. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
5. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
6. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
7. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
8. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-preclinical studies in a nude mouse model
9. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
10. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
11. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
12. Discovery of (R)-7-cyano-2, 3, 4, (phenylmethyl)-4-(2-thienylsulfony)-1H-1, 4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity
13. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
14. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
15. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
16. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
17. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:Protein transferase inhibitor
18. Farnesyltransferase and geranylgeranyl-transferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
19. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
20. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts
21. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells
22. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
23. CENP-E function at kinetochores is essential for chromosome alignment
24. Characterization of the kinetochore binding domain of CENP-E reveals interactions with the kinetochore proteins CENP-F and hBUBR1
25. CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment
26. Cytoplasmic dynein plays a role in mammalian mitotic spindle formation
27. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo
28. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen
29. The geranylgeranyltransferase-1 inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-indenpendent manner
30. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing